However, such a combination should be considered in patients with T2DM and ASCVD/Indicators of High Risk or CKD who have not reached the target HbA1C despite the use of SGLT2 inhibitor or GLP1-R agonist in monotherapy. Here, GLP1R is linked to chronic kidney disease.